Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
Status:
Terminated
Trial end date:
2008-08-20
Target enrollment:
Participant gender:
Summary
Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate
cancer cells and either kill them or deliver radioactive cancer-killing substances to them
without harming normal cells. Motexafin gadolinium may increase the effectiveness of yttrium
Y 90 ibritumomab tiuxetan by making the cancer cells more sensitive to the drug.
This phase I/II trial is studying the side effects and best dose of motexafin gadolinium when
administered with rituximab and yttrium Y 90 ibritumomab tiuxetan and to see how well they
work in treating patients with stage II, stage III, or stage IV relapsed or refractory
non-Hodgkin's lymphoma.